FY2025 Earnings Estimate for Qiagen Issued By Zacks Research

Key Points

• Analysts at Zacks Research have raised their FY2025 earnings per share estimate for Qiagen to $2.33, slightly up from the previous estimate of $2.32.
• Qiagen recently reported a quarterly earnings per share of $0.55, exceeding analysts' expectations of $0.50, with revenue of $483.46 million, a year-over-year increase of 5.2%.
• The stock currently has a consensus rating of "Hold" among analysts, with an average target price of $49.40.

Qiagen N.V. (NYSE:QGEN - Free Report) - Stock analysts at Zacks Research upped their FY2025 earnings per share estimates for Qiagen in a research note issued to investors on Tuesday, July 22nd. Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.33 per share for the year, up from their previous forecast of $2.32. The consensus estimate for Qiagen's current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen's FY2027 earnings at $2.71 EPS.

Qiagen (NYSE:QGEN - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The company had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. During the same quarter in the prior year, the company earned $0.44 earnings per share. Qiagen's revenue was up 5.2% on a year-over-year basis.

Several other equities research analysts have also issued reports on the company. Wall Street Zen raised Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 15th. Barclays assumed coverage on Qiagen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price on the stock. Robert W. Baird boosted their target price on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Bank of America boosted their price target on Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Finally, Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Seven equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $49.40.

Qiagen Stock Performance

NYSE:QGEN opened at $51.30 on Friday. The company has a current ratio of 3.37, a quick ratio of 2.83 and a debt-to-equity ratio of 0.40. Qiagen has a 12-month low of $37.63 and a 12-month high of $51.58. The stock has a 50-day moving average price of $46.57 and a 200 day moving average price of $43.16. The stock has a market capitalization of $11.40 billion, a P/E ratio of 128.61, a P/E/G ratio of 2.56 and a beta of 0.68.

Qiagen Announces Dividend

The business also recently declared a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were given a dividend of $0.25 per share. The ex-dividend date was Wednesday, July 2nd. This represents a dividend yield of 0.52%. Qiagen's payout ratio is 62.50%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of QGEN. Groupama Asset Managment grew its stake in shares of Qiagen by 8,074.0% during the 4th quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock valued at $1,416,844,000 after buying an additional 32,216,761 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Qiagen by 9.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock valued at $1,127,470,000 after purchasing an additional 2,202,040 shares in the last quarter. Wellington Management Group LLP raised its stake in Qiagen by 12.2% during the first quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company's stock worth $972,191,000 after acquiring an additional 2,656,136 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Qiagen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company's stock worth $397,937,000 after purchasing an additional 77,119 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of Qiagen by 57.5% in the 1st quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after acquiring an additional 1,639,621 shares during the period. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.